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Objectives. This study assessed whether combination therapy
with aspirin and warfarin for 10 weeks reduces the risk of
progression or reocclusion of the unstable coronary artery lesion.
Background. Reocclusion of the culprit coronary artery occurs
in up to one third of patients during the 3 months after myocar-
dial infarction (MI) or unstable angina and is associated with
increased morbidity and mortality.
Methods. Fifty-seven patients presenting with unstable angina
or MI who had an identifiable culprit lesion at coronary angiog-
raphy were randomized in double-blind manner to receive warfa-
rin (target international normalized ratio [INR] 2.0 to 2.5) or
placebo in addition to aspirin (150 mg daily). Changes in the
culprit lesion were assessed by quantitative angiography in 50
patients after 10 weeks of therapy or after a clinical event.
Progression of the culprit lesion was defined as a decrease in
minimal lumen diameter >0.4 mm or a new total occlusion.
Regression was defined as an increase in minimal lumen diameter
>0.4 mm.
Results. In subjects randomized to receive warfarin, the culprit
lesion was less likely to progress (1 [4%] vs. 8 [33%]) and more
likely to regress (5[19%] vs. 2[9%]) than in subjects receiving
placebo (p 5 0.02). Recurrent MI or a new occlusion at angiog-
raphy occurred in 2 (7%) of 29 patients receiving warfarin versus
11 (39%) of 28 patients receiving placebo (p 5 0.005).
Conclusions. In patients with an acute coronary syndrome,
combined therapy with aspirin and warfarin with a target INR of
2.0 to 2.5 for 10 weeks reduces the risk of progression or
reocclusion of the culprit coronary lesion.
(J Am Coll Cardiol 1997;30:364–9)
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There is an increased risk of recurrent coronary events during
the first few weeks after an acute ischemic event (1). After the
acute event, the ruptured atherosclerotic plaque remains po-
tentially unstable with angiographic evidence of overlying
thrombus and continued activation of procoagulant and in-
flammatory mediators (2). This condition predisposes to fur-
ther thrombus formation and a risk of progression or reocclu-
sion of the culprit coronary lesion. Both antiplatelet (3,4) and
antithrombin (5–7) therapies reduce the risk of myocardial
infarction (MI) when given separately. By simultaneously
inhibiting different pathways of thrombogenesis, combined
antiplatelet and antithrombin therapy has the potential to
more effectively reduce new thrombus formation over a fis-
sured plaque. The aim of this study was to determine whether
combination treatment with low dose aspirin and warfarin or
administration of aspirin alone for 10 weeks after an episode of
unstable coronary disease more favorably influenced the cul-
prit lesion.
Methods
Study patients. Patients were eligible for inclusion in the
study if 1) they had had an acute MI or unstable angina with
onset of symptoms ,48 h before admission to the hospital; 2)
the culprit coronary lesion could be identified at angiography
performed 36 h to 8 days after admission; 3) the patient’s
clinical status was stable and the patient’s physician did not
consider early revascularization indicated; and 4) there was no
recognized contraindication to anticoagulation with warfarin.
Participants gave written informed consent and the study
protocol was approved by the institutional ethics committee.
Myocardial infarction was defined as 1) acute onset isch-
emic chest pain of .20 min duration, 2) new Q waves (Q wave
MI) or isolated T wave inversion (non-Q wave MI) on the
electrocardiogram; and 3) an increase in creatine kinase .2
times the upper limit of normal. Patients with ST segment
elevation $1 mV in at least two leads ($2 mV in precordial
leads) were treated with intravenous streptokinase or tissue
plasminogen activator. Unstable angina was defined as 1) new
onset ischemic chest pain of .20 min duration; 2) transient ST
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segment depression $0.1 mV or T wave inversion; and 3)
serum creatine kinase ,2 times the upper limit of normal. All
patients received intravenous heparin to maintain activated
partial thromboplastin time at 2 times the control level and
oral aspirin (150 to 300 mg daily).
Study protocol. Within 6 h of coronary angiography sub-
jects were randomized in a double-blind manner to receive
warfarin or placebo. Stratified randomization with randomly
generated numbers was used to maintain similar proportions
of patients with unstable angina and MI. The dose of warfarin
was 10 mg for 2 days, then adjusted to the target international
normalized ratio (INR) of 2.0 to 2.5. To maintain blinded
treatment, INR tests were performed on all study patients and
the dose was adjusted by a physician not involved with clinical
management or angiographic analysis. Matched dose adjust-
ment was undertaken in patients randomized to placebo, and
INR results were not reported. After randomization all pa-
tients received subcutaneous heparin (12,500 U twice daily) for
3 days and aspirin (150 mg daily) for the duration of the study.
Other medications were adjusted as clinically indicated.
Trial therapy was discontinued early for bleeding, clinical
events (including myocardial infarction, death, coronary angio-
plasty, coronary artery bypass grafting) or withdrawal of pa-
tient consent. Trial medication was discontinued 2 days before
follow-up angiography planned for 10 weeks after randomiza-
tion.
Angiographic analysis. Antianginal therapy, contrast me-
dia and the sequence of angiographic projections were docu-
mented at the baseline angiogram; these conditions were
duplicated at the follow-up angiogram. All patients received
sublingual glyceryl trinitrate spray, 800 mg, before angiography
was performed. Paired films were later evaluated by a cardiol-
ogist who had no knowledge of treatment by using dual
projectors to match frames for orientation and vessel filling.
The projection that optimally visualized the maximal stenosis
of the culprit lesion was chosen for analysis. Three sequential
end diastolic frames were marked for digitization. Quantitative
coronary angiography was then performed without knowledge
of treatment, patient identity or temporal order by using the
Ancor coronary analysis system (Siemens). The coronary cath-
eter was used for calibration to determine absolute measure-
ments in millimeters. After selection of a segment, the arterial
borders were defined by an automatic edge detection algo-
rithm and measurements displayed automatically. For each
lesion the mean of measurements made on three end-diastolic
frames was calculated (8).
Variability between baseline and follow-up angiograms was
assessed in 34 nonculprit lesions. The standard deviation of the
difference was 0.08 mm for repeat measurements of the same
view and 0.18 mm for equivalent views obtained 2 months
apart. Lesion progression or regression was defined as a
change .0.4 mm (.2 SD of the 2-month variability) or a
change from a patent (Thrombolysis in Myocardial Infarction
[TIMI] flow grade 2 or 3) to an occluded (TIMI grade 0 or 1
flow) vessel. These criteria are similar to those used in previous
reports (9–12).
Analysis and statistics. The primary end point of the study
was the mean change in the minimal lumen diameter of the
culprit coronary lesion between baseline and follow-up angiog-
raphy. The sample size of 50 paired angiograms was chosen to
detect a 0.30-mm difference between the two treatments
assuming an SD of 0.36 mm with a power of 0.80 and alpha
0.05. Change in percent stenosis of the culprit lesion and the
proportion of patients with progression/regression or progres-
sion to occlusion of the culprit lesion were secondary end
points of the study. The combined end point of progression to
occlusion on angiography or MI was not defined prospectively.
Two-sided t tests were used to compare the two treatment
groups for continuous variables. The Fisher exact test was used
to compare the proportions of categoric variables in each
group. Statistical analysis was performed by using SPSS. A
p value ,0.05 was regarded as statistically significant.
For patients randomized to warfarin, the proportion of time
spent in each INR range was calculated by using a computer
program that assumes a linear change between two consecutive
INR measurements (13).
Results
Fifty-seven patients were randomized to receive warfarin
(i.e., aspirin plus warfarin, n 5 29) or aspirin alone (i.e., aspirin
plus placebo, n 5 28). Baseline characteristics for the two
treatment groups were similar (Table 1). For the patients
assigned to warfarin the median INR was 2.0. The percent of
Abbreviations and Acronyms
CARS 5 Coumadin Aspirin Reinfarction Study
INR 5 international normalized ratio
MI 5 myocardial infarction
TIMI 5 Thrombolysis in Myocardial Infarction
Table 1. Baseline Clinical and Angiographic Characteristics of the
Two Patient Groups
Placebo 1 Aspirin
(n 5 28)
Warfarin 1 Aspirin
(n 5 29)
Mean age (yr) 56.8 56.9
Male 25 24
Previous MI 4 10
Smoker 13 9
UA or non-Q wave MI 11 10
Q wave MI 17 19
Thrombolysis 18 18
CAD $50% stenosis
1-vessel 13 9
2-vessel 10 15
3-vessel 5 5
Unless otherwise indicated, data are presented as number of patients.
CAD 5 coronary artery disease; MI 5 myocardial infarction; UA 5 unstable
angina.
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patient time spent within each INR range is presented in
Figure 1.
Clinical events. Table 2 provides details of the clinical
events in each treatment group. One patient randomized to
aspirin alone died after recurrent MI 5 days after randomiza-
tion. Including this event, one patient (3%) randomized to
warfarin and six patients (21%) randomized to aspirin alone
had recurrent MI (p 5 0.052). Differences in the incidence of
death, MI or revascularization between patients randomized to
warfarin and patients receiving aspirin alone were not statisti-
cally significant (5 [17%] vs. 9 [32%], p 5 0.23).
Three patients randomized to warfarin discontinued ther-
apy because of bleeding. One patient had major bleeding
(INR 5 2.5) requiring transfusion and oversewing of a duode-
nal ulcer 5 days after randomization. The other two patients
had minor bleeding.
Angiographic results. Baseline angiography was per-
formed a median of 3 days (range 1.5 to 8) after admission;
follow-up angiography was performed 64 days (range 3 to 78)
after randomization. In 11 patients angiography was per-
formed early because of a clinical event (median 40 days [range
3 to 69]). Follow-up angiography was not performed in seven
patients (four randomized to aspirin alone and three to
warfarin, Table 2).
At baseline, the mean minimal lumen diameter and percent
stenosis of the culprit lesion were similar for the two treatment
groups (Table 3). At follow-up, there was a decrease in mean
minimal lumen diameter and an increase in the percent
diameter stenosis in patients randomized to aspirin alone. The
culprit lesion had regressed in two of these patients but had
progressed in eight (in seven to total occlusion). For patients
randomized to warfarin, the mean minimal lumen diameter did
not decrease during follow-up; only one patient had progres-
sion to total occlusion and five had regression of the culprit
lesion (Table 4). Differences between treatment groups in
mean minimal lumen diameter and percent diameter stenosis
were statistically significant.
Relation between recurrent coronary events and angio-
graphic changes. Of the eight patients with progression to
occlusion at follow-up angiography, two had had an MI and
two unstable angina. The other four patients had asymptom-
atic occlusion at the site of the culprit coronary lesion.
Follow-up angiography was performed in six of the seven
patients who had recurrent MI (one patient died). Progression
to occlusion was confirmed in two patients. Although the other
four patients had patent arteries, they underwent angiography
after receiving a thrombolytic drug or heparin, or both. Recur-
rent MI or angiographic evidence of occlusion occurred in 2
(7%) of 29 patients randomized to warfarin versus 11 (39%) of
28 randomized to aspirin alone (p 5 0.005).
Discussion
Prevention of late reocclusion with warfarin plus aspirin.
In this study, combination treatment with warfarin and aspirin
was more successful in maintaining the average minimal lumen
diameter and in reducing the incidence of progression and new
occlusion of the culprit coronary lesion than was conventional
therapy with aspirin alone. The study was designed to detect
both progression and regression of the culprit lesion, but the
most frequent change was progression from a patent to an
occluded artery; an observation also made in other studies
(14). This finding implies that in most cases lesion progression
Figure 1. Percent of patient time within each international normalized
ratio (INR) range.
Table 2. Timing of Clinical Events or Withdrawal of Study Medication
Placebo 1 Aspirin (n 5 28) Warfarin 1 Aspirin (n 5 29)
No. of Pts Days After Randomization No. of Pts Days After Randomization
Cardiac events
Death 1 5* 0
MI 5 0, 2, 31, 44, 69 1 15
CABG 2 31, 56* 1 33†
PTCA 1 64 3 40, 58, 48
Bleeding events
Major‡ 0 1 5*
Minor§ 0 2 5,*† 24*
Withdrawal of consent 2 1,* 3* 0
*These patients (n 5 7) had no second angiogram. †This patient stopped warfarin therapy on day 5 after minor
bleeding, then underwent CABG on day 33. ‡Bleeding leading to transfusion, intracranial hemorrhage or death. §Other
bleeding. CABG 5 coronary artery bypass grafting; MI 5 myocardial infarction; Pts 5 patients; PTCA 5 percutaneous
transluminal coronary angioplasty.
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is due to recurrent thrombosis rather than to gradual remod-
eling and that the combination of warfarin and aspirin reduces
the risk of new thrombus formation.
The rate of reocclusion in this study of 29% for subjects
receiving aspirin alone is similar to the reocclusion rate at 3
months of 25% to 32% reported in other studies (15,16). In
previous angiographic studies, treatment with warfarin alone
or with combined aspirin and dipyridamole did not differ from
placebo (15,17) in reducing the rate of reocclusion. In this
study, the reocclusion rate for patients receiving warfarin and
aspirin was only 4% and there was a significant reduction in the
combined end point of either progression to occlusion or MI.
Relation between angiographic progression and clinical
events. The importance of angiographic progression to occlu-
sion has been well documented. After MI, left ventricular
function is worse in patients with reocclusion without reinfarc-
tion than in those with a patent artery (18,19). Reocclusion of
the culprit coronary artery is also associated with increased
morbidity and mortality (19,20). It is therefore likely that
preventing reocclusion will improve long-term prognosis even
for patients in whom reocclusion is clinically silent.
Angiographic and clinical measures of progression were not
always concordant. It is known that progression to occlusion can
occur in patients whose clinical status remains stable (14,16,18).
In addition, several of our patients had recurrent MI during
follow-up but had no change in the culprit lesion at subsequent
angiography. In these patients it is likely that recurrent thrombo-
sis at the culprit lesion was followed by thrombolysis.
Comparison with previous studies. In previous studies, the
combination of heparin and aspirin for 5 days in patients with
unstable coronary disease either showed no significant benefit
over heparin or aspirin alone (21) or resulted in fewer events
during treatment but no difference during longer follow-up (1).
Although these observations may be partly explained by a
rebound increase in events after withdrawal of heparin (22),
they also emphasize the need for a longer duration of combi-
nation therapy to cover the period when the risk of recurrent
events remains high.
The value of combined antiplatelet and antithrombin ther-
apy suggested by this study is supported by recent studies with
clinical end points. In two studies (23,24) low molecular weight
heparin and aspirin taken for 3 months after an acute coronary
event significantly reduced the number of recurrent events.
The Antithrombotic Therapy in Acute Coronary Syndromes
(ATACS) study (25) suggested a benefit of combined warfarin
(INR 2 to 3) and aspirin (162.5 mg daily) commenced soon after
hospital admission with a reduction in total ischemic events in the
combination group versus aspirin alone (13% vs. 25%).
These results appear to conflict with a preliminary report
from the Coumadin Aspirin Reinfarction Study (CARS) that
found no benefit for combined Coumadin and aspirin com-
pared with aspirin alone.* There are several possible explana-
tions for this difference. In the CARS study the dose of aspirin
was lower (80 mg/day) for patients randomized to Coumadin
than for those randomized to placebo (160 mg/day). A fixed
dose of Coumadin (1 mg or 3 mg) was used and a lower
intensity of anticoagulation was achieved than in the current
study or in earlier studies in which long-term anticoagulation
reduced the risk of MI (5–7). In the CARS study treatment was
started up to 3 weeks after the acute coronary event, but it is
known that the greatest risk for recurrent events is during the
1st 2 to 3 weeks after the index event (1,23). Early introduction
of combination therapy and rapid achievement of target levels
of anticoagulation may be needed to exert a significant impact
on the culprit coronary lesion.
Study limitations. The study group was a selected cohort
of patients who had early angiography but were not referred
for early angioplasty or coronary artery bypass surgery. In our
*Fuster V. Low-dose Coumadin plus low-dose aspirin following myocardial
infarction (CARS trial). Presented at the 45th Annual Scientific Session of the
American College of Cardiology, March 1996, Orlando, Florida.
Table 3. Quantitative Coronary Angiographic Measurements
Placebo 1 Aspirin
(n 5 24)
(mean 6 SD)
Warfarin 1 Aspirin
(n 5 26)
(mean 6 SD)
Difference Between
Treatment Groups
(mean [95% CI]) p Value
Minimal lumen diameter (mm)
Baseline 0.74 6 0.52 0.73 6 0.34
Follow-up 0.50 6 0.55 0.77 6 0.36
Change 20.24 6 0.51 0.04 6 0.32 0.28 [0.04 to 0.52] 0.025
Percent stenosis (%)
Baseline 75.3 6 17.2 74.3 6 11.3
Follow-up 82.3 6 18.4 72.1 6 12.7
Change 7.0 6 19.0 22.2 6 10.7 29.2 [20.58 to 217.9] 0.039
CI 5 confidence interval.
Table 4. Change in Culprit Lesion
Minimal Lumen Diameter
Change .0.4 mm
Placebo 1 Aspirin
(n 5 24)
Warfarin 1
Aspirin
(n 5 26)
Progression 8 (33%) 1 (4%)
Unchanged 14 (58%) 20 (77%)
Regression 2 (9%) 5 (19%)
p 5 0.02 by Fisher exact test. Data presented are number (%) of patient
group.
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center ;30% of patients admitted with unstable angina or MI
have early coronary angiography, and 15% to 20% undergo
early revascularization by angioplasty or surgery. In New
Zealand publicly funded access to coronary angioplasty and
bypass surgery is restricted, with priority given to patients with
ongoing ischemia, an early positive exercise test result or more
extensive coronary artery disease.
Our study included patients with both MI and unstable
angina. Differences in the use of thrombolytic therapy and the
timing of the first angiogram may influence the severity of the
culprit stenosis. The importance of these factors in determin-
ing the response to combination antithrombotic therapy is
uncertain and could not be determined from the current study,
which is too small to allow a useful subgroup analysis.
The study was not designed and had insufficient power to
detect clinically important differences in morbidity or mortality
between treatment allocations. Quantitative angiographic
measures were chosen as the primary end points because they
provide a more precise estimate of the effects of treatment on
the culprit coronary lesion than do clinical events alone. The
sample size was small, but it was sufficient to detect a statisti-
cally significant difference in progression of the culprit lesion
with the use of more than one angiographic measure.
The combined clinical and angiographic end point of reoc-
clusion or MI was not prospectively defined. This combined
end point was included because several patients had clinical
evidence of reocclusion of the culprit coronary artery but no
change either at the culprit lesion or at other sites on subse-
quent angiography. Including an assessment of clinical as well
as angiographic end points may also reduce the potential for
bias that could occur if patients without a follow-up angiogram
were excluded from the analysis.
The current study was too small to reliably evaluate the
safety of combined warfarin and aspirin. In previous larger
studies (25,26) the risk of minor bleeding was increased for
patients treated with this combination. However, the risk of
major bleeding is not increased provided the INR is between
1.5 and 3.0 and aspirin dose is #150 mg daily (26–28).
Combined aspirin and warfarin with a target INR of 2.0 to 2.5
for 10 weeks may have a net benefit despite a small increase in
bleeding risk because of the much higher absolute risk of
recurrent cardiac events in the early period after presentation
with unstable coronary artery disease.
Conclusions. Combined therapy with aspirin (150 mg
daily) and warfarin with a target INR of 2.0 to 2.5 for 10 weeks
after unstable angina or acute MI reduces the risk of progres-
sion or reocclusion of the unstable coronary lesion. This
finding suggests that patients with an acute coronary syndrome
may benefit from treatment with a combination of warfarin
and aspirin that is started early and continued for several
weeks or months. Because our study group was small, these
conclusions are preliminary and further studies are needed to
determine whether this therapeutic approach improves clinical
as well as angiographic outcome.
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